StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report published on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
GNCA opened at $0.00 on Thursday. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market cap of $5,873.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.
About Genocea Biosciences
Featured Articles
- Five stocks we like better than Genocea Biosciences
- Basic Materials Stocks Investing
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What is a Bond Market Holiday? How to Invest and Trade
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Stock Market Sectors: What Are They and How Many Are There?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.